Skip to content

Novavax NVAX Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$9.49M-102%$17.53M+122%-$202.38M-66.8%$106.51M-34.4%$518.65M+452%
$3.06M-63.3%$5.13M-59.1%$6.59M-48.1%$7.56M-32.1%$8.34M-31.3%
$7.72M-24.9%$7.97M-23.7%$8.55M-29.0%$9.21M-34.6%$10.29M-11.0%
-$32.42M+82.5%-$39.48M+77.2%-$127.46M-141%-$185.5M-122%
$1.27M-20.4%$2.08M+7.5%$2.02M+47.0%$0-100%$1.6M-76.8%
-$28.36M+61.3%-$136.53M$111.1M+130%-$73.32M-911%
$46.41M$0
$37.68M+634%$42.44M-$1.04M-100%-$7.06M-220%
-$23.13M+91.3%-$27.31M+36.9%$0+100%-$9.5M-105%-$266.81M-204%
-$33.69M+82.0%-$41.55M+76.3%-$127.33M-141%-$187.1M-107%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Novavax generate?
Novavax (NVAX) generated -$384.9M in operating cash flow over the trailing twelve months.
What is Novavax's free cash flow?
After $5.4M of capital expenditures, Novavax's free cash flow was -$389.7M over the trailing twelve months, down 288.4% year over year.
Where does Novavax's cash flow data come from?
Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.